Last updated on February 2020

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization


Brief description of study

The purpose of this study is to determine the efficacy and safety of AR101 in peanutallergic children aged 1 to < 4 years.

Detailed Study Description

To determine the efficacy and safety of AR101 in a characterized oral desensitization immunotherapy (CODIT) regimen compared with placebo in peanutallergic children aged 1 to < 4 years.

Clinical Study Identifier: NCT03736447

Find a site near you

Start Over

Arkansas Children's Hospital

Little Rock, AR United States
  Connect »

Peninsula Research Associates, Inc.

Rolling Hills Estates, CA United States
  Connect »

Atlantic Research Center

Ocean City, NJ United States
  Connect »

The John Hopkins Hospital

Baltimore, MD United States
  Connect »

Clinical Research of Charlotte

Charlotte, NC United States
  Connect »

James Paget University Hospital

Gorleston-on-Sea, United Kingdom
  Connect »

Leicester Royal Infirmary

Leicester, United Kingdom
  Connect »

University of Frankfurt

Frankfurt am Main, Germany
  Connect »